Previous 10 | Next 10 |
HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipeline and upcom...
HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to ...
Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...
The LD Micro Index topped 2000 in early June, capping a marathon run that began in March. With that spectacular climb, the index has regained the perch it held before the first coronavirus cases in the United States were reported. This is welcome news for small-cap investors, many of whom migh...
Last week was another good one for healthcare stocks across the board, and a stellar week for investors holding shares of these recent high flyers. Now that they've made some big gains, investors are right to wonder if there's more fuel in the tank. Here's what you need to know about what...
Shares of Celldex Therapeutics (NASDAQ: CLDX) , a clinical-stage biotechnology company, are rising in response to insider stock purchases and large equity stakes acquired by independent investment firms. A stock market encouraged by the signs of confidence has driven shares 29.2% higher as of...
HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exe...
Celldex Therapeutics (NASDAQ: CLDX ) has priced its public offering of 13,377,926 common shares at $9.75/share, for expected gross proceeds of ~$130.4M. More news on: Celldex Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stoc...
Celldex Therapeutics ( CLDX ) is a development stage pharmaceutical company. It was once a high flyer, reaching the equivalent of $402.15 per share in 2015 before its lead candidate failed a Phase 3 trial. More recently, before the CDX-0159 news was announced, it was selling at about $3.00 per...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...